FindTrial
Sign In

The effect of changes in the pharmacokinetics of polymyxin E sodium methanesulfonate in a population supported by ECMO in vitro and the study of the mechanism

Population pharmacokinetics of polymyxin E sodium methanesulfonate in critically ill patients receiving extracorporeal membrane oxygenation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101490
Enrollment
Unknown
Registered
2025-04-25
Start date
2024-11-25
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute or chronic infections caused by sensitive strains of gram-negative bacilli

Interventions

ECMO:NA
Non-ECMO:NA

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. receive polymyxin E sodium mesylate; 2. Admission to ICU; 3. Age >= 18 years;

Exclusion criteria

Exclusion criteria: 1. Allergic to polymyxin E sodium mesylate; 2. Undergoing plasmapheresis; 3. pregnancy; 4. refusing to participate;

Design outcomes

Primary

MeasureTime frame
drug concentration;—

Secondary

MeasureTime frame
Models of ECMO;total bilirubin;direct bilirubin;Alanine aminotransferase;Aspartate aminotransferase;Alkaline phosphatase;Gamma-glutamyltransferase;Lactate dehydrogenase;TotalProtein;Albumin;blood urea nitrogen;serum creatinine;Creatinine Clearance;sequential organ failure assessment;Acute Physiology and Chronic Health Evaluation II;white blood cell;procalcitonin;microbiology;—

Countries

China

Contacts

Public ContactXiaomei Chen

Qilu Hospital of Shandong University

chenxm008@163.com+86 18560081002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026